At a glance
ClinicalIndex Comparison RecordPhase 2Unknown· 80 target
Drug / intervention
Apatinib +1 moredrug
Likely dose
Apatinib 425mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase Ⅱ Study of Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences·interventional·Posted Dec 14, 2018·Updated Dec 14, 2018
In Brief
A Phase 2 clinical trial evaluating Apatinib and capecitabine for Triple-negative Breast Cancer. Targeting 80 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus capecitabine or capecitabine for maintenance therapy of patients with with advanced triple-negative breast cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTriple-negative Breast Cancer
CountriesChina
Collaborators--
Timeline
Phase 2UnknownOverdue
20192020202120222023202420252026
First PostedDec 2018
Enrollment StartDec 2018
Primary CompletionDec 2020
Study CompletionOct 2021
TodayJul 2026
First PostedDec 14, 2018
Enrollment StartDec 18, 2018
Primary CompletionDec 1, 2020
Study CompletionOct 1, 2021
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 7.5 years ago
Interventions
Apatinibdrug
apatinib 425mg qd po
capecitabinedrug
capecitabine 1000mg/m2 bid d1-d14